Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333514 | 0.87 | HIF1A (0.45) | NR1H4MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL18287880 | 0.84 | MAPT (0.47) | NR1H4MAPTALDH1A1MAPK1NPC1 | |
| SCHEMBL97898 | 0.83 | PARP10 (0.48) | ALDH1A1LMNATDP1KMT2AGAA | |
| SCHEMBL10977168 | 0.83 | PARP10 (0.48) | ALDH1A1LMNATDP1KMT2AGAA | |
| SCHEMBL17961880 | 0.83 | PARP10 (0.48) | ALDH1A1LMNATDP1KMT2AGAA | |
| SCHEMBL799946 | 0.82 | NR1H4 (0.57) | NR1H4MAPTALDH1A1MAPK1NPC1 | |
| SCHEMBL7301353 | 0.81 | TRPV1 (0.65) | NR1H4MAPTALDH1A1MAPK1NPC1 | |
| SCHEMBL7603042 | 0.80 | NR1H4 (0.36) | NR1H4MAPTNPC1RAB9ALMNA | |
| SCHEMBL6515056 | 0.80 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL9016172 | 0.80 | NPC1 (0.51) | MAPTNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543455-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | Enalare Therapeutics Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4504206-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250031718-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | SOVIDA SOLUTIONS LTD (GB) | 2025-01-30 | — | — | US | disclosed |
| US-12150461-B2 | Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof | Sovida Solutions Ltd. (GB) | 2024-11-26 | — | — | US | disclosed |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | ENALARE THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118829433-A | Respiratory stimulant parenteral formulations | 依那拉治疗股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4426308-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | Enalare Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118488840-A | Methods of treating respiratory depression modulated by non-opioid agents | 依那拉治疗股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2022234336-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022197581-A1 | NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT | TAURIGA SCIENCES INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20220296561-A1 | NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT | TAURIGA SCIENCES INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-9145417-B2 | Optical performance humidity dependency improving agent for cellulose acylate film | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20110262661-A1 | Optical performance humidity dependency improving agent for cellulose acylate film | FUJIFILM CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| WO-2006016218-A1 | ARYL OR HETEROARYL CARBONYL DERIVATIVES DERIVATIVES USEFUL AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
| WO-1998052995-A1 | METHOD FOR THE PRODUCTION OF A BRANCHED MACROMOLECULE, THE BRANCHED MACROMOLECULE AND USES THEREOF | DSM N.V. (NL) | 1998-11-26 | — | — | WO | disclosed |
| EP-0746310-A1 | CONTROLLED RELEASE COMPOSITION | BUKH MEDITEC A/S (DK) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995022962-A1 | CONTROLLED RELEASE COMPOSITION | BM RESEARCH A/S (DK) | 1995-08-31 | — | — | WO | disclosed |
| US-4238625-A | ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | OPRK1, OPRM1, OPRD1 | NR1H4 866/4885MAPT 3664/4885ALDH1A1 481/4885 |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | NR1H4 866/4885MAPT 3664/4885ALDH1A1 481/4885 |
| US-20110262661-A1 | Optical performance humidity dependency improving agent for cellulose acylate film | ALKBH1, ACOT7, ALKBH2 | NR1H4 1875/4885MAPT 221/4885ALDH1A1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.